MaaT Pharma
Entity

  • MaaT Pharma

    Created in 2014
  • BETA

    Up & running (A)
    Existing signals show a regular activity

  • Social networks

    12,396

  • Activities

    biotech deeptech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    70 Av. Tony Garnier, 69007 Lyon, France

    Lyon

    France

  • Employees

    Scale: 51-200

    Estimated: 77

  • SIREN

    808370100

  • Engaged corporates

    25
    8 21

  • Added in Motherbase

    4 years, 6 months ago
Description
  • Value proposition

    The leading microbiome company in oncology

    MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.
    Hervé Affagard, CEO & Co-founder


    Microbiome, Microbiota, Microbiology, pharma, GvHD, Leukemia, Dysbiosis, Symbiosis, Biotech, oncology, cancer, gut microbiota, allo-HSCT, and Gut microbiome

  • Original language

    The leading microbiome company in oncology

    MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.
    Hervé Affagard, CEO & Co-founder

  • MaaT Pharma - Building a leading microbiome company in oncology

    We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.

    • https://www.maatpharma.com/
Corporate interactions BETA
Corporate TypeTweets Articles
BFM Business
BFM Business
Media, Broadcast Media Production and Distribution
BFM Business
Media, Broadcast Media Production and Distribution 		Other

26 Sep 2023


Bpifrance
Bpifrance
Bank, Banking
Bpifrance
Bank, Banking 		Not capitalistic
Partnership
Event

30 Sep 2022


ONLYLYON
ONLYLYON
National and local authorities, Non-profit Organizations
ONLYLYON
National and local authorities, Non-profit Organizations 		Not capitalistic
Not partnership
Event

1 Feb 2023


INRAE
INRAE
Research, Research Services
INRAE
Research, Research Services 		Not capitalistic
Not partnership
Event

25 Mar 2024


Le Figaro
Le Figaro
Media, Newspaper Publishing
Le Figaro
Media, Newspaper Publishing 		Not capitalistic
Not partnership
Event

3 Jan 2023


Similar entities
Last news
Show all articles
Social network dynamics